IRIS

Jessen, F., Arbizu, J., Boada, M., Balasa, M., Bennys, K., Boban, M., et al. (2025). Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease. JPAD, 12(8) [10.1016/j.tjpad.2025.100259].

Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease

Plantone, Domenico;
2025-01-01
2025
JPAD
Jessen, F., Arbizu, J., Boada, M., Balasa, M., Bennys, K., Boban, M., et al. (2025). Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease. JPAD, 12(8) [10.1016/j.tjpad.2025.100259].
1.1 Articolo in rivista
File in questo prodotto:
File Dimensione Formato  
Comment by European Alzheimer’s Disease Consortium-Jessen-2025.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 340.6 kB
Formato Adobe PDF
Visualizza/Apri
340.6 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1297218